Biotechnology in Germany industry profile provides top-line qualitative and quantitative summary information including: market size (value 2012-16, and forecast to 2021). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.
Save time carrying out entry-level research by identifying the size, growth, major segments, and leading players in the biotechnology market in Germany
Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the biotechnology market in Germany
Leading company profiles reveal details of key biotechnology market players' global operations and financial performance
Add weight to presentations and pitches by understanding the future growth prospects of the Germany biotechnology market with five year forecasts
Reasons To Buy
What was the size of the Germany biotechnology market by value in 2016?
What will be the size of the Germany biotechnology market in 2021?
What factors are affecting the strength of competition in the Germany biotechnology market?
How has the market performed over the last five years?
What are the main segments that make up Germany's biotechnology market?
The biotechnology market consists of the development, manufacturing, and marketing of products based on advanced biotechnology research.
The German biotechnology market is expected to generate total revenues of $8.7bn in 2016, representing a compound annual growth rate (CAGR) of 7% between 2012 and 2016.
The Medical/Healthcare segment is expected to be the market's most lucrative in 2016, with total revenues of $4.3bn, equivalent to 49.7% of the market's overall value.
There is strong interest in the German biotech industry from foreign players. Japanese Astelles Pharma has entered negotiations to buy Ganymed Pharmaceuticals in order to gain access to the highly regarded cancer antibody technology.
Market value forecast
Market value forecast
Five Forces Analysis
Threat of substitutes
Degree of rivalry
Boehringer Ingelheim GmbH
Merck & Co., Inc.
Related MarketLine research
Figure 1: Germany biotechnology industry value: $ million, 2012-16(e)
Figure 2: Germany biotechnology industry category segmentation: % share, by value, 2016(e)
Figure 3: Germany biotechnology industry geography segmentation: % share, by value, 2016(e)
Figure 4: Germany biotechnology industry value forecast: $ million, 2016-21
Figure 5: Forces driving competition in the biotechnology industry in Germany, 2016
Figure 6: Drivers of buyer power in the biotechnology industry in Germany, 2016
Figure 7: Drivers of supplier power in the biotechnology industry in Germany, 2016
Figure 8: Factors influencing the likelihood of new entrants in the biotechnology industry in Germany, 2016
Figure 9: Factors influencing the threat of substitutes in the biotechnology industry in Germany, 2016
Figure 10: Drivers of degree of rivalry in the biotechnology industry in Germany, 2016
Figure 11: Boehringer Ingelheim GmbH: revenues & profitability
Figure 12: Boehringer Ingelheim GmbH: assets & liabilities
Figure 13: Merck & Co., Inc.: revenues & profitability
Figure 14: Merck & Co., Inc.: assets & liabilities
Figure 15: MorphoSys AG: revenues & profitability
Figure 16: MorphoSys AG: assets & liabilities
Table 1: Germany biotechnology industry value: $ million, 2012-16(e)
Table 2: Germany biotechnology industry category segmentation: $ million, 2016(e)
Table 3: Germany biotechnology industry geography segmentation: $ billion, 2016(e)
Table 4: Germany biotechnology industry value forecast: $ million, 2016-21
Table 5: Boehringer Ingelheim GmbH: key facts
Table 6: Boehringer Ingelheim GmbH: key financials ($)
Table 7: Boehringer Ingelheim GmbH: key financials (EUR)
Table 8: Boehringer Ingelheim GmbH: key financial ratios
Table 9: Merck & Co., Inc.: key facts
Table 10: Merck & Co., Inc.: key financials ($)
Table 11: Merck & Co., Inc.: key financial ratios
Table 12: MorphoSys AG: key facts
Table 13: MorphoSys AG: key financials ($)
Table 14: MorphoSys AG: key financials (EUR)
Table 15: MorphoSys AG: key financial ratios
Table 16: Germany size of population (million), 2012-16
Table 17: Germany gdp (constant 2005 prices, $ billion), 2012-16
Table 18: Germany gdp (current prices, $ billion), 2012-16
Table 19: Germany inflation, 2012-16
Table 20: Germany consumer price index (absolute), 2012-16
Table 21: Germany exchange rate, 2012-16
Single User License:
Corporate User License:
Boehringer Ingelheim GmbH Merck & Co., Inc. MorphoSys AG
Biotechnology, MarketLine, Germany
select a license
NEWSLETTER BY CATEGORY
An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ... "General Manager SBU Manufacture, PT. KIMIA FARMA, TBK"
Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process.... "VP Innovation, Engineered Profiles LLC"
Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed... "President, VPP E-Data Services, VPP E-Data Services"
The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements.... "Senior Associate, Booz Allen Hamilton"
This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"